Compare AER & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | BIIB |
|---|---|---|
| Founded | 1995 | 1978 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 24.2B |
| IPO Year | 2006 | 1991 |
| Metric | AER | BIIB |
|---|---|---|
| Price | $140.98 | $174.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 22 |
| Target Price | $146.29 | ★ $177.40 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 63.90 | N/A |
| EPS | ★ 20.89 | 10.97 |
| Revenue | $8,344,637,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $4.58 | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.68 | $15.86 |
| Revenue Growth | ★ 6.67 | 4.77 |
| 52 Week Low | $85.57 | $110.04 |
| 52 Week High | $142.25 | $185.17 |
| Indicator | AER | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 55.35 |
| Support Level | $131.62 | $169.24 |
| Resistance Level | $142.25 | $180.79 |
| Average True Range (ATR) | 2.41 | 5.03 |
| MACD | 0.22 | -1.63 |
| Stochastic Oscillator | 90.32 | 36.29 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties.It has one business segment: leasing, financing, sales and management of commercial flight equipment (Commercial Flight Equipment Segment).Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include United Kingdom, United States, and Other countries.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).